Kala Pharmaceuticals Inc

NASDAQ:KALA   12:46:19 AM EDT
5.74
+0.04 (+0.70%)
: $5.63 -0.11 (-1.92%)
Earnings Announcements

Kala Pharmaceuticals Reports Third Quarter Results

Published: 11/08/2022 13:19 GMT
Kala Pharmaceuticals Inc (KALA) - Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update.
Ended Quarter With $52.4 Million in Cash; Sufficient for Funding Operations Into 2q 2024.
Kala - Planning to Initiate Phase 2/3 Trial of Kpi-012 for Persistent Corneal Epithelial Defect (pced) in 4q 2022; Topline Data Expected in 1q 2024.
Qtrly Net Income per Share Attributable to Common Stockholders—diluted $19.25.
Q3 Earnings per Share View $10.75 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$6.79

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$5.96

More details on our Analysts Page.